HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Public ClinicalTrials.gov record NCT04153149. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
HELIOS-B: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will evaluate the efficacy and safety of vutrisiran 25 mg administered subcutaneously (SC) once every 3 months (q3M) compared to placebo in participants with ATTR amyloidosis with cardiomyopathy.
Study identification
- NCT ID
- NCT04153149
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 655 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years to 85 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 26, 2019 (Actual)
- Primary completion
- May 8, 2024 (Actual)
- Completion
- Dec 2, 2026 (Estimated)
- Last update posted
- Jan 12, 2026
2019 – 2026
United States locations
- U.S. sites
- 17
- U.S. states
- 11
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Clinical Trial Site | La Mesa | California | 91942 | — |
| Clinical Trial Site | Los Angeles | California | 90033 | — |
| Clinical Trial Site | Stanford | California | 94305 | — |
| Clinical Trial Site | Washington D.C. | District of Columbia | 20010 | — |
| Clinical Trial Site | Gainesville | Georgia | 30501 | — |
| Clinical Trial Site | Chicago | Illinois | 60637 | — |
| Clinical Trial Site | Evanston | Illinois | 60201 | — |
| Clinical Trial Site | Boston | Massachusetts | 02115 | — |
| Clinical Trial Site | Boston | Massachusetts | 02118 | — |
| Clinical Trial Site | Rochester | Minnesota | 55902 | — |
| Clinical Trial Site | Manhasset | New York | 11030 | — |
| Clinical Trial Site | New York | New York | 10032 | — |
| Clinical Trial Site | Durham | North Carolina | 27710 | — |
| Clinical Trial Site | Cleveland | Ohio | 44195 | — |
| Clinical Trial Site | Allentown | Pennsylvania | 18103 | — |
| Clinical Trial Site | Philadelphia | Pennsylvania | 19104 | — |
| Clinical Trial Site | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 102 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04153149, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 12, 2026 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04153149 live on ClinicalTrials.gov.